NR565 Advanced Pharmacology
Midterm Study Guide-Graded A
Drugs that APRNs can prescribe - ANS-Schedule 3-5 drugs
Determined by State Boards of Nursing, Medicine, and Pharmacy - ANS-Prescriptive
authority regulation
Leads to fewer treatment options for patients, requiring them to find providers with
authority - ANS-Limited prescriptive authority impact
Understanding prescribed drugs, their effects, contraindications, and ensuring correct
dosages - ANS-Key responsibilities of prescribing
Acronym for CYP450 enzyme inducers: Barbiturates, St. John's Wort, Carbamazepine,
Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas - ANS-
BSCRAP GPS Incudes Rage
Amount of active drug reaching systemic circulation from administration site - ANS-
Bioavailability
Include forgetfulness, lack of planning, cost, dissatisfaction, and altered dosing - ANS-
Reasons for medication nonadherence
Absorption is slow in neonates due to low muscle blood flow; absorption becomes rapid
in early infancy - ANS-IM administration in neonates and infants
Gastric emptying time is prolonged and irregular in early infancy, affecting drug
absorption - ANS-Oral administration in neonates/infants
Based on body surface area (BSA) calculation - ANS-Dosage determination for
pediatric patients
Steps include defining the problem, setting therapeutic objectives, choosing treatment,
verifying its suitability, starting treatment, giving information, and monitoring treatment -
ANS-Guiding principles for prescribers
Examples include Valproate, Isoniazid, Sulfonamides, Amiodarone, Chloramphenicol,
Ketoconazole, Grapefruit juice, Quinidine - ANS-CYP450 inhibitors
, Basis for prescribing decisions, considering drug interactions and effects on target
receptors - ANS-Pharmacokinetics and pharmacodynamics
Tool identifying inappropriate medication use in older adults, cautioning against certain
drugs and interactions - ANS-Beer's Criteria
Include adverse drug events, increased healthcare interactions, cognitive impairment,
reduced adherence, falls, and mortality - ANS-Impacts of polypharmacy
They decrease medication metabolism - ANS-CYP450 inhibitors function
May cause toxicity if enzymes are inactive or ineffectiveness if enzymes are overactive -
ANS-CYP450 inhibitors consequences
Occurs when CYP2D6 alleles have inactivating mutations, leading to enzyme synthesis
with impaired or no activity - ANS-Poor metabolism phenotype
Ensures safety, efficiency, and security of human and veterinary drugs, biological
products, and medical devices - ANS-US FDA regulation
Include heroin, oxycodone, methadone, and morphine. - ANS-Pure Opioid Agonists
Include naloxone, methylnaltrexone, and naloxegol. - ANS-Pure Opioid Antagonists
Include pentazocine, buprenorphine, and nalbuphine. - ANS-Agonist-Antagonist Opioids
Predicts overdose risk based on a 5-item measure. - ANS-Opioid Risk Tool (ORT)
Database tracking patient's controlled substance history. - ANS-Prescription Drug
Monitoring Program
Includes prior overdose, misuse, high doses, and benzodiazepines. - ANS-Naloxone
Prescription Criteria
Include attendance drop, secretive behavior, and friend changes. - ANS-Behavioral
Signs of Drug Abuse
Include personality change, mood swings, and paranoia. - ANS-Psychological Signs of
Drug Abuse
High abuse potential requiring written prescriptions. - ANS-Schedule II Drugs
Include heroin, LSD, marijuana, and methaqualone. - ANS-Schedule I Drugs
Moderate abuse potential, like codeine products and steroids. - ANS-Schedule III Drugs
Midterm Study Guide-Graded A
Drugs that APRNs can prescribe - ANS-Schedule 3-5 drugs
Determined by State Boards of Nursing, Medicine, and Pharmacy - ANS-Prescriptive
authority regulation
Leads to fewer treatment options for patients, requiring them to find providers with
authority - ANS-Limited prescriptive authority impact
Understanding prescribed drugs, their effects, contraindications, and ensuring correct
dosages - ANS-Key responsibilities of prescribing
Acronym for CYP450 enzyme inducers: Barbiturates, St. John's Wort, Carbamazepine,
Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas - ANS-
BSCRAP GPS Incudes Rage
Amount of active drug reaching systemic circulation from administration site - ANS-
Bioavailability
Include forgetfulness, lack of planning, cost, dissatisfaction, and altered dosing - ANS-
Reasons for medication nonadherence
Absorption is slow in neonates due to low muscle blood flow; absorption becomes rapid
in early infancy - ANS-IM administration in neonates and infants
Gastric emptying time is prolonged and irregular in early infancy, affecting drug
absorption - ANS-Oral administration in neonates/infants
Based on body surface area (BSA) calculation - ANS-Dosage determination for
pediatric patients
Steps include defining the problem, setting therapeutic objectives, choosing treatment,
verifying its suitability, starting treatment, giving information, and monitoring treatment -
ANS-Guiding principles for prescribers
Examples include Valproate, Isoniazid, Sulfonamides, Amiodarone, Chloramphenicol,
Ketoconazole, Grapefruit juice, Quinidine - ANS-CYP450 inhibitors
, Basis for prescribing decisions, considering drug interactions and effects on target
receptors - ANS-Pharmacokinetics and pharmacodynamics
Tool identifying inappropriate medication use in older adults, cautioning against certain
drugs and interactions - ANS-Beer's Criteria
Include adverse drug events, increased healthcare interactions, cognitive impairment,
reduced adherence, falls, and mortality - ANS-Impacts of polypharmacy
They decrease medication metabolism - ANS-CYP450 inhibitors function
May cause toxicity if enzymes are inactive or ineffectiveness if enzymes are overactive -
ANS-CYP450 inhibitors consequences
Occurs when CYP2D6 alleles have inactivating mutations, leading to enzyme synthesis
with impaired or no activity - ANS-Poor metabolism phenotype
Ensures safety, efficiency, and security of human and veterinary drugs, biological
products, and medical devices - ANS-US FDA regulation
Include heroin, oxycodone, methadone, and morphine. - ANS-Pure Opioid Agonists
Include naloxone, methylnaltrexone, and naloxegol. - ANS-Pure Opioid Antagonists
Include pentazocine, buprenorphine, and nalbuphine. - ANS-Agonist-Antagonist Opioids
Predicts overdose risk based on a 5-item measure. - ANS-Opioid Risk Tool (ORT)
Database tracking patient's controlled substance history. - ANS-Prescription Drug
Monitoring Program
Includes prior overdose, misuse, high doses, and benzodiazepines. - ANS-Naloxone
Prescription Criteria
Include attendance drop, secretive behavior, and friend changes. - ANS-Behavioral
Signs of Drug Abuse
Include personality change, mood swings, and paranoia. - ANS-Psychological Signs of
Drug Abuse
High abuse potential requiring written prescriptions. - ANS-Schedule II Drugs
Include heroin, LSD, marijuana, and methaqualone. - ANS-Schedule I Drugs
Moderate abuse potential, like codeine products and steroids. - ANS-Schedule III Drugs
